Rituximab Use During Pregnancy and Its Effects on Neonatal B-Cell Development
Author Information
Author(s): D. T. Klink, R. M. van Elburg, M. W. J. Schreurs, G. T. J. van Well
Primary Institution: VU University Medical Center
Hypothesis
Does rituximab administration during the third trimester of pregnancy affect neonatal B-cell development?
Conclusion
Rituximab administration during pregnancy appears to be safe for the child, with no reported complications.
Supporting Evidence
- Rituximab levels in the mother and neonate were measured, showing a significant difference.
- At birth, B-lymphocytes were not detectable in the neonate.
- Normal growth and development were observed in the neonate up to 10 months of age.
- No adverse events were reported for the fetus and neonate.
- Vaccination titres were adequate after 10 months.
Takeaway
Giving a medicine called rituximab to pregnant women doesn't seem to hurt their babies, and the babies grow up healthy.
Methodology
The study involved administering rituximab to a pregnant woman and monitoring the effects on her newborn, including measuring rituximab levels and B-cell counts.
Limitations
The study is based on a limited number of case reports, which may not provide a comprehensive understanding of the effects.
Participant Demographics
The case involved a 36-year-old woman with a history of idiopathic thrombocytopenic purpura.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website